Teva Pharmaceutical

Teva Pharmaceutical Industries Limited (TEVA) – “Pivot to Growth” strategy gaining momentum

in , , on October 10, 2023

Teva Pharmaceutical Industries Limited (TEVA) (Q2FY23)

Stock PerformanceTeva Pharmaceutical’s stock price showed an upward trend in past 3 months. It gave 40.45% returns during the period. The stock price increased by 20.2% in past 1-year. The stock has a 52-week high of $11.45 and its 52-week low is $7.09.

In the past 3 years, the stock has given returns of 11.71%. TEVA has a 50-day moving Avg. and 200-day moving Avg. of $9.36 and $9.04, respectively.

Revenue Performance – TEVA revenues were $3,878mn in Q2FY23, an increase of 2% compared to Q2FY22. In local currency terms, revenues increased by 4%, mainly due to higher revenues from AUSTEDO and Anda in North America segment and from generic products in International Markets segment, partially offset by lower revenues from generic products and from COPAXONE ® in North America segment as well as from API sales to third parties.

Company Guidance for FY23 – TEVA expect Revenues of $15.0 – $15.4bn, Operating Income of 4.0 – 4.4bn, Adjusted EBITDA of 4.5 – 4.9bn, Finance Expenses ($m) of ~1,000. The company expect tax rate of 14% – 17%, Diluted EPS of 2.25 – 2.55. It expect Free Cash Flow of 1.7 – 2.1bn for FY23.


AUSTEDO is on course to achieve its target of reaching $1.2 billion in sales for the year 2023. This update underscores the company’s progress in meeting its financial goals and indicates that they are making significant strides towards hitting their revenue target.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.



– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– PE Band Comparison
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

No of Pages: 35

To Download other equity/ stock reports CLICK HERE

Follow our LinkedIn page for more updates.

Release Information

  • Price


  • Released

    October 10, 2023

  • Last Updated

    October 10, 2023